332 related articles for article (PubMed ID: 34778489)
1. Antifungal Susceptibility Testing: A Primer for Clinicians.
Wiederhold NP
Open Forum Infect Dis; 2021 Nov; 8(11):ofab444. PubMed ID: 34778489
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of antifungal susceptibility: Review of literature.
Hadrich I; Ayadi A
J Mycol Med; 2018 Sep; 28(3):574-584. PubMed ID: 29773435
[TBL] [Abstract][Full Text] [Related]
4. Antifungal susceptibility testing: a primer for clinicians.
Kuper KM; Coyle EA; Wanger A
Pharmacotherapy; 2012 Dec; 32(12):1112-22. PubMed ID: 23165897
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of antifungal susceptibility testing.
Eschenauer GA; Carver PL
Pharmacotherapy; 2013 May; 33(5):465-75. PubMed ID: 23553342
[TBL] [Abstract][Full Text] [Related]
6. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).
Arendrup MC; Friberg N; Mares M; Kahlmeter G; Meletiadis J; Guinea J;
Clin Microbiol Infect; 2020 Nov; 26(11):1464-1472. PubMed ID: 32562861
[TBL] [Abstract][Full Text] [Related]
7. Role of antifungal susceptibility testing in patient management.
Forrest G
Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility testing. New technology and clinical applications.
Pfaller MA; Yu WL
Infect Dis Clin North Am; 2001 Dec; 15(4):1227-61. PubMed ID: 11780273
[TBL] [Abstract][Full Text] [Related]
9. Clinical Usefulness of Susceptibility Breakpoints for Yeasts in the Treatment of Candidemia: A Noninterventional Study.
Lass-Flörl C; Krause R; Willinger B; Starzengruber P; Decristoforo P; Neururer S; Kreidl P; Aigner M
J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32498436
[TBL] [Abstract][Full Text] [Related]
10. Breakpoints for posaconazole susceptibility testing: background and discussion about the need of establishing values.
Fleck R; Hof H
Mycoses; 2008 Sep; 51 Suppl 2():1-4. PubMed ID: 18721327
[TBL] [Abstract][Full Text] [Related]
11. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
12. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
13. Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.
Lamoth F; Lewis RE; Kontoyiannis DP
J Fungi (Basel); 2020 Dec; 7(1):. PubMed ID: 33396870
[TBL] [Abstract][Full Text] [Related]
14. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.
Albataineh MT; Sutton DA; Fothergill AW; Wiederhold NP
Infect Dis Clin North Am; 2016 Mar; 30(1):13-35. PubMed ID: 26739605
[TBL] [Abstract][Full Text] [Related]
15. Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds.
Lamoth F; Alexander BD
J Clin Microbiol; 2015 Oct; 53(10):3176-81. PubMed ID: 26202113
[TBL] [Abstract][Full Text] [Related]
16. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.
Rex JH; Pfaller MA; Galgiani JN; Bartlett MS; Espinel-Ingroff A; Ghannoum MA; Lancaster M; Odds FC; Rinaldi MG; Walsh TJ; Barry AL
Clin Infect Dis; 1997 Feb; 24(2):235-47. PubMed ID: 9114154
[TBL] [Abstract][Full Text] [Related]
17. Impact of real-time fungal susceptibility on clinical practices.
Magiorakos AP; Hadley S
Curr Opin Infect Dis; 2004 Dec; 17(6):511-5. PubMed ID: 15640704
[TBL] [Abstract][Full Text] [Related]
18. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
19. EUCAST breakpoints for antifungals.
Rodríguez-Tudela JL; Arendrup MC; Cuenca-Estrella M; Donnelly JP; Lass-Flörl C
Drug News Perspect; 2010 Mar; 23(2):93-7. PubMed ID: 20369073
[TBL] [Abstract][Full Text] [Related]
20. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species.
Morris AJ; Rogers K; McKinney WP; Roberts SA; Freeman JT
J Glob Antimicrob Resist; 2018 Sep; 14():72-77. PubMed ID: 29486358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
